Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 13; no. 9; p. 222
• Main Authors: Jamwal, Rohitash, Barlock, Benjamin J.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 29.08.2020; MDPI
• Subjects: CYP450; Cytochrome; Diabetes; drug metabolism; Enzymes; Fatty acids; Inflammation; Insulin resistance; LC–MS/MS; Liver diseases; Metabolic syndrome; NAFLD; NASH; Obesity; Pathogenesis; proteomics; Researchers; Review; Triglycerides; Weight control; NAFLD; proteomics; CYP450; drug metabolism; PBPK; NASH; LC–MS/MS
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph13090222

Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive fat in the liver. An international consensus panel has recently proposed to rename the disease to metabolic dysfunction associated with fatty liver disease (MAFLD). The disease can range from simple steatosis (fat accumulation) to nonalcoholic steatohepatitis (NASH) which represents a severe form of NAFLD and is accompanied by inflammation, fibrosis, and hepatocyte damage in addition to significant steatosis. This review collates current knowledge of changes in human hepatic cytochrome P450 enzymes in NAFLD. While the expression of these enzymes is well studied in healthy volunteers, our understanding of the alterations of these proteins in NAFLD is limited. Much of the existing knowledge on the subject is derived from preclinical studies, and clinical translation of these findings is poor. Wherever available, the effect of NAFLD on these proteins in humans is debatable and currently lacks a consensus among different reports. Protein expression is an important in vitro physiological parameter controlling the pharmacokinetics of drugs and the last decade has seen a rise in the accurate estimation of these proteins for use with physiologically based pharmacokinetic (PBPK) modeling to predict drug pharmacokinetics in special populations. The application of label-free, mass spectrometry-based quantitative proteomics as a promising tool to study NAFLD-associated changes has also been discussed.